Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

130 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Symptomatic COVID-19 course and outcomes after three mRNA vaccine doses in multiple sclerosis patients treated with high-efficacy DMTs.
Capuano R, Prosperini L, Altieri M, Lorefice L, Fantozzi R, Cavalla P, Guaschino C, Radaelli M, Cordioli C, Nociti V, Boffa L, Ragonese P, Di Gregorio M, Pinardi F, Torri Clerici V, De Luca G, Gajofatto A, Paolicelli D, Tortorella C, Gasperini C, Solaro C, Cocco E, Bisecco A, Gallo A. Capuano R, et al. Among authors: di gregorio m. Mult Scler. 2023 Jun;29(7):856-865. doi: 10.1177/13524585231167515. Epub 2023 May 11. Mult Scler. 2023. PMID: 37165941 Free PMC article.
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study.
Prosperini L, Annovazzi P, Boffa L, Buscarinu MC, Gallo A, Matta M, Moiola L, Musu L, Perini P, Avolio C, Barcella V, Bianco A, Farina D, Ferraro E, Pontecorvo S, Granella F, Grimaldi LME, Laroni A, Lus G, Patti F, Pucci E, Pasca M, Sarchielli P; Italian Alemtuzumab Study Group. Prosperini L, et al. J Neurol. 2018 Dec;265(12):2851-2860. doi: 10.1007/s00415-018-9070-x. Epub 2018 Sep 26. J Neurol. 2018. PMID: 30259178
Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study.
Di Gregorio M, Torri Clerici VLA, Fenu G, Gaetani L, Gallo A, Cavalla P, Ragonese P, Annovazzi P, Gajofatto A, Prosperini L, Landi D, Nicoletti CG, Di Carmine C, Totaro R, Nociti V, De Fino C, Ferraro D, Tomassini V, Tortorella C, Righini I, Amato MP, Manni A, Paolicelli D, Iaffaldano P, Lanzillo R, Moccia M, Buttari F, Fantozzi R, Cerqua R, Zagaglia S, Farina D, De Luca G, Buscarinu MC, Pinardi F, Cocco E, Gasperini C, Solaro CM, Di Filippo M. Di Gregorio M, et al. Among authors: di carmine c, di filippo m. Eur J Neurol. 2021 Apr;28(4):1299-1307. doi: 10.1111/ene.14672. Epub 2021 Jan 12. Eur J Neurol. 2021. PMID: 33305459
Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study.
Lanzillo R, Carotenuto A, Signoriello E, Iodice R, Miele G, Bisecco A, Maniscalco GT, Sinisi L, Romano F, Di Gregorio M, Lavorgna L, Trojsi F, Moccia M, Fratta M, Capasso N, Dubbioso R, Petracca M, Spiezia AL, Gallo A, Petruzzo M, De Angelis M, Bonavita S, Lus G, Tedeschi G, Brescia Morra V. Lanzillo R, et al. Among authors: di gregorio m. J Clin Med. 2022 Apr 7;11(8):2081. doi: 10.3390/jcm11082081. J Clin Med. 2022. PMID: 35456175 Free PMC article.
130 results